Dr. Fox is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
16040 Park Valley Dr
Ste 100
Round Rock, TX 78681Phone+1 512-218-1222Fax+1 512-218-1393
Education & Training
- Baylor College of MedicineResidency, Neurology, 1989 - 1992
- Baylor College of MedicineInternship, Internal Medicine, 1988 - 1989
- Baylor College of MedicineClass of 1988
Certifications & Licensure
- TX State Medical License 1990 - 2026
- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis Start of enrollment: 2007 Nov 01
- Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Start of enrollment: 2011 Sep 08
- Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis Patients Start of enrollment: 2011 May 01
Publications & Presentations
PubMed
- 690 citationsDetection of ultra-rare mutations by next-generation sequencingMichael W. Schmitt, Scott R. Kennedy, Jesse J. Salk, Edward J. Fox, Joseph Hiatt
Proceedings of the National Academy of Sciences of the United States of America. 2012-09-04 - 138 citationsMechanism of action of mitoxantroneEdward Fox
Neurology. 2004-12-28 - 107 citationsVagal afferent innervation of smooth muscle in the stomach and duodenum of the mouse: morphology and topography.Edward A. Fox, Robert J. Phillips, Fred A. Martinson, Elizabeth A. Baronowsky, Terry L. Powley
The Journal of Comparative Neurology. 2000-12-18
Press Mentions
- The University of Illinois School of Medicine Rockford Is Considering Adding a New $ 100 Million Building to Its Campus for Rural Health SciencesAugust 13th, 2021
- #AAN2019 — Ublituximab Safe, Well-Tolerated in Extension Study of Phase 2 Trial in Relapsing MSMarch 15th, 2019
- #ECTRIMS2018 – Ublituximab Markedly Reduces Lesions, Promotes B-cell Depletion, Halts Disability Progression in Phase 2 TrialSeptember 28th, 2018
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: